In patients with atherosclerotic cardiovascular disease, continued treatment with bempedoic acid for up to 2.5 years effectively keeps levels of low-density lipoprotein cholesterol (LDL-C) low, while also being generally well-tolerated, according to the results of a phase 3, open-label extension (OLE) study.